Research
Immunotherapy Effectiveness for Recurrent Hodgkin's Disease
Immunomodulation After High Dose Myeloablative Therapy With Autologous Stem Cell Rescue for Refractory/Relapsed Hodgkin's Disease
Protocol Description
This Phase II/III multi-center trial is studying the effectiveness of high-dose chemotherapy followed by autologous stem cell transplantation, cyclosporine, interferon gamma, and interleukin-2 as compared to high-dose chemotherapy followed by autologous stem cell transplantation only in treating patients with refractory or relapsed Hodgkin's lymphoma. Combining chemotherapy with autologous stem cell transplantation – transplanting the donor’s own stem cells – may allow physicians to give higher doses of chemotherapy drugs and kill more cancer cells.
Eligibility Criteria
Eligible candidates include children and young adults up through age 29 with Hodgkin disease that did not get better after initial treatment or that went away and then came back.
Males: Up through age 29
Females: Up through age 29
Requirements*
Participants will receive 2 courses of salvage induction therapy followed by protocol therapy within 2-5 weeks after. Phase II protocol includes immunotherapy and additional chemotherapy, and may also include radio therapy. In the Phase III portion of the study, participants are randomized into 2 groups – a repeat of Phase II protocol or Phase II protocol minus immunotherapy.
Visits: Number of visits will vary depending on the participant’s response to treatment.
Duration: This study is expected to take approximately one year and involves yearly follow-up examinations thereafter.
Status: Closed to Enrollment
Source of Support
Children’s Oncology Group
National Cancer Institute
Additional Resources
Children’s Oncology Group CureSearch
Study Description at National Institutes of Health
Primary Investigator(s)
Peter H. Shaw, MD
Contact Information
To get started, please contact:
Peter Shaw, MD
412-692-5055
